Parkinson's disease, the second common
neurodegenerative disease is clinically characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) with upregulation of neuroinflammatory markers and oxidative stress. Autophagy lysosome pathway (ALP) plays a major role in degradation of damaged organelles and
proteins for energy balance and intracellular homeostasis. However, dysfunction of ALP results in impairment of α-
synuclein clearance which hastens dopaminergic neurons loss. In this study, we wanted to understand the neuroprotective efficacy of Val in
rotenone induced PD rat model. Animals received
intraperitoneal injections (2.5 mg/kg) of
rotenone daily followed by Val (40 mg/kg, i.p) for four weeks.
Valeric acid, a straight chain alkyl
carboxylic acid found naturally in Valeriana officianilis have been used in the treatment of
neurological disorders. However, their neuroprotective efficacy has not yet been studied. In our study, we found that Val prevented
rotenone induced upregulation of pro-inflammatory
cytokine oxidative stress, and α-
synuclein expression with subsequent increase in vital
antioxidant enzymes. Moreover, Val mitigated
rotenone induced hyperactivation of microglia and astrocytes. These protective mechanisms prevented
rotenone induced dopaminergic neuron loss in SNpc and neuronal fibers in the striatum. Additionally, Val treatment prevented
rotenone blocked mTOR-mediated
p70S6K pathway as well as apoptosis. Moreover, Val prevented
rotenone mediated autophagic vacuole accumulation and increased lysosomal degradation. Hence, Val could be further developed as a potential therapeutic candidate for treatment of PD.